• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Case Control Study EvaIuation of biomarkers, genetic mutations, and epigenetic modifications in earIy diagnosis of pancreatic cancer

    2021-10-12 08:47:00BilalRahManzoorAhmadBandayGhRasoolBhatOmarShahHumiraJeelaniFizalahKawoosaTahiraYousufDilAfroze
    World Journal of Gastroenterology 2021年36期

    Bilal Rah, Manzoor Ahmad Banday, Gh Rasool Bhat, Omar J Shah, Humira Jeelani, Fizalah Kawoosa, Tahira Yousuf, Dil Afroze

    Abstract BACKGROUND Pancreatic cancer (PC) is one of the deadliest malignancies with an alarming mortality rate.Despite significant advancement in diagnostics and therapeutics,early diagnosis remains elusive causing poor prognosis, marred by mutations and epigenetic modifications in key genes which contribute to disease progression.AIM To evaluate the various biological tumor markers collectively for early diagnosis which could act as prognostic biomarkers and helps in future therapeutics of PC in Kashmir valley.METHODS A total of 50 confirmed PC cases were included in the study to evaluate the levels of carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide specific antigen (TPS),carcinoembryonic antigen (CEA), vascular endothelial growth factor-A (VEGF-A),and epidermal growth factor receptor (EGFR).Mutational analysis was performed to evaluate the mutations in Kirsten rat sarcoma (KRAS), Breast cancer type 2 (BRCA-2), and deleted in pancreatic cancer-4 (DPC-4) genes.However, epigenetic modifications (methylation of CpG islands) were performed in the promoter regions of cyclin-dependent kinase inhibitor 2A (p16; CDKN2A), MutL homolog 1(hMLH1), and Ras association domain-containing protein 1(RASSF1A) genes.RESULTS We found significantly elevated levels of biological markers CA 19-9 (P ≤ 0.05),TPS (P ≤ 0.05), CEA (P ≤ 0.001), and VEGF (P ≤ 0.001).Molecular genetic analysis revealed that KRAS gene mutation is predominant in codon 12 (16 subjects, P ≤0.05), and 13 (12 subjects, P ≤ 0.05).However, we did not find a mutation in DPC-4(1203G > T) and BRCA-2 (617delT) genes.Furthermore, epigenetic modification revealed that CpG methylation in 21 (P ≤ 0.05) and 4 subjects in the promoter regions of the p16 and hMLH1 gene, respectively.CONCLUSION In conclusion, CA 19-9, TPS, CEA, and VEGF levels were significantly elevated and collectively have potential as diagnostic and prognostic markers in PC.Global data of mutation in the KRAS gene commonly in codon 12 and rare in codon 13 could augment the predisposition towards PC.Additionally, methylation of the p16 gene could also modulate transcription of genes thereby increasing the predisposition and susceptibility towards PC.

    Key Words: Pancreatic cancer; Genetic mutations; Epigenetic modifications; Biomarkers;Risk factors; Diagnostics

    INTRODUCTION

    Pancreatic cancer (PC) is one of the deadliest malignancies among several solid malignancies.It is the 15thleading cancer in the world with an overall estimated incidence of 277000 new cases which is being diagnosed every year[1].In the United States, PC is the fourth leading cause of death with a 5-year survival rate of less than 5%[2].PC is mostly found in elderly people and has been reported to be associated with several risk factors[3].The predominant risk factors include age, cigarette smoking, a high-fat diet, decreased serum levels of folate, diabetes mellitus, obesity,and chronic pancreatitis[4,5].The familial history of pancreatitis increases the probability of developing PC by around 40%[6].PC has the lowest prognosis among several solid-type tumors, mainly because almost 80% of PC patients are diagnosed when the disease is in the advanced or metastatic stage[7].Owing to the lack of specific biological biomarkers used in clinical practice for the detection of PC and its nonspecific symptomology at the initial stage of the malignancy, the early diagnosis is extremely critical to detect and analyze disease progression[8].Therefore, it is vital to identify specific biomarkers that play a key role in early diagnosis thereby improving the management and therapeutic outcome in PC.

    Tumor biomarker(s) are the substances that can be examined in body fluids (blood,urine, and other fluids), synthesized and excreted by malignant cells within the tumor tissue besides exceeding the normal level potentiating its use for cancer diagnosis and/or prognosis[9].Thus, ideally, the tumor markers should have high sensitivity and specificity, however, none of the tumor biomarkers have attained such precision[10].Recent reports suggest that commonly used biomarkers for various malignancies include carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide specific antigen (TPS),carcinoembryonic antigen (CEA), vascular endothelial growth factor-A (VEGF-A), and epidermal growth factor receptor (EGFR)[11].The CA 19-9 and CEA are high molecular weight glycoproteins attached to the surface of tumor cells predominantly used in the diagnosis and prognosis of gut-associated cancers.However, marred by low sensitivity and specificity, they far from qualify for the diagnosis of other cancers[12].The group of intermediate filament proteins to which TPS belongs is mainly used to measure cytokeratin 18 and 19 and expected to reflect the tumor progression.A few studies have examined TPS expression in PC; however, the findings are contentious.Although, individually TPS expression in PC may not provide significant information about the disease progression; in concert with other tumor biological markers it is worthwhile to evaluate its role for early diagnosis, prognosis, and to predict metastatic growth of PC[13].A predominant dimeric, heparin-associated glycoprotein, VEGF-A has powerful pro-angiogenic and mitogenic activity.Elevated expression of VEGF-A enhances vascular permeability of endothelial cells and is reported to be involved in PC-associated angiogenesis[14], thus potentiates as a predictive biomarker.EGFR is a transmembrane protein that regulates cell growth and development.Mutation or elevated expression of EGFR is a key event in the pathogenesis of various malignancies such as glioblastoma, lung and oral carcinomas.There are reports of EGFR-mediated signaling associated with EGFR mutation in PC patients[15].Consequently, these reports suggest that evaluation of serum EGFR levels in PC can be a promising putative biomarker for early diagnosis and prognosis to monitor the disease status post-therapeutic interventions.Although, individually the tumor biomarkers could aid in diagnostic and prognostic evaluation to a certain level,however, collectively, they can be more beneficial to track tumor progression and could be more useful to monitor disease status.Therefore, the current study aims to evaluate the collective role of various tumor biomarkers in PC patients for their potential role in early diagnosis and application in prognosis to examine posttreatment disease status in the ethnic Kashmiri population.

    Genetic mutations play a pivotal role in tumor progression and genetic markers are critically important for the detection of malignant changes in PC[16].Approximately,97% of PC patients have alterations in genes that either follow the germline inheritance mode of transmission or occur sporadically[17].These mutations could be either oncogenic (gain of function) or diminish tumor suppressor activity (loss of function).Gain-of-function in Kirsten rat sarcoma (KRAS)a proto-oncogene that encodes guanosine triphosphatase (GTPase), is one of the prominent mediators in signal transduction pathways that are implicated in neoplastic transformation and inflammation[18].Approximately 95% of all cancers including PC are reported to harbor aKRASgene mutation which is a key event in early tumorigenesis.The majorKRASactivating gene mutations reportedly occur at codon 12 and less commonly at codon 13 and codon 61.Therefore, evaluation of genetic mutational analysis at the hotspot regions of theKRASgene could help in early diagnosis and prognosis in PC.Breast cancer type 2(BRCA-2), a tumor suppressor gene is associated with the maintenance of the genome by enhancing homologous recombination of a double-stranded break.Around 80% ofBRCA-2mutations are either frameshift or nonsense mutations that result in the formation of premature stop codons to encode non-functional BRCA-2 protein[19].Almost 7.3% of PC patients have a hereditary mutation in theBRCA-2gene which increases the risk of developing PC by approximately 20-fold[20]implicating a critical role ofBRCA-2in the early diagnosis of PC.Another vital gene,‘deleted in pancreatic cancer-4’(DPC-4)also known as SMAD family member 4,mothers against decapentaplegic homolog 4 (SMAD-4)is a tumor suppressor gene involved in the regulation of gene transcription.DPC-4 protein a downstream target of transforming growth factor-beta (TGF-β) pathway plays a critical role in the activation of TGF-β signaling thereby promotes neoplastic growth.It is reported that 30% of PC cases develop due to homozygous mutations in theDPC-4gene[21,22].Thus,mutational analysis of theDPC-4gene could be a promising factor for the early diagnosis and prognosis of PC.

    Besides genetic mutations, recent evidence suggests the epigenetic modifications such as DNA methylation plays a critical role in the pathogenesis of PC.In the recent past, reports suggest that methylation at the promoter regions of key tumor suppressor genes induces gene silencing and contributes to the development and progression of tumorigenesis[23].Various tumor suppressor genes were inactivated by epigenetic modifications.Cyclin-dependent kinase inhibitor 2A (p16; CDKN2A), a tumor suppressor gene that encodes a member of cyclin-dependent kinase inhibitor which arrests the G1-S phase of the cell cycle to prevent tumor cell progression.Loss of thep16gene is reported in 70% of cancers and around 10%-15% of the loss was due to promoter methylation[24].Thus, screening of epigenetic modifications at the promoter region of thep16gene could help in the early diagnosis of PC.MutL homolog 1 (hMLH1)a tumor suppressor gene that belongs to the mismatched repair gene family and prevents DNA damage by radiations and other associated mechanisms.hMLH1is also reported to be inactivated epigenetically by promoter methylation which leads to DNA damage.The accumulation of mismatched and damaged DNA promotes tumor cell progression[25].Ras association domain-containing protein 1(RASSF1A)is another tumor suppressor gene inactivated by promoter methylation.It is a component of RAS/PI3K/AKT and RAS/MAPK pathways.Recent reports suggest that epigenetic modifications in theRASSF1Apromoter region promote tumor progression in various cancers including kidney, breast, lung, prostate, and thyroid[26].Recent evidence suggests that 64% of pancreatic adenocarcinoma patients haveRASSF1Ahypermethylation at the promoter region, indicating that analysis of hypermethylation ofRASSF1Aat promoter region could be a promising approach for early diagnosis of PC.To summarize, these studies suggest that genetic mutations, epigenetic modulations,and elevated levels of serum biological markers play a critical role in the early diagnosis, therapeutics, and prognosis of various cancer.Therefore, keeping in consideration the documented role of tumor biomarkers, genetic mutations, and DNA methylation of tumor suppressor/protooncogenes in various malignancies including PC.The current study aimed to evaluate the serum levels of various biological tumor markers, genetic mutations, and epigenetic modifications of some key regulatory genes in PC.This would prove immensely helpful in the early diagnosis of PC, which helps in the identification of high-risk PC and may enable their development as biomarkers for future diagnostics, therapeutic interventions, and prognostics in the ethnic Kashmiri population.

    MATERIALS AND METHODS

    In this study, a total of 50 patients with pancreatic carcinoma and 50 healthy controls were included.

    Inclusion criteria

    Only the patients with histologically confirmed pancreatic carcinoma were included in this study.Written consent was taken at the very beginning from all the patients and healthy controls that were included in the study.

    Exclusion criteria

    The patients with a history of other malignancies and those who were not willing to comply with pre-requisite protocol were excluded from the study.

    Physical examination and lifestyle habits

    The study was designed and approved by the institutional review board of the Sher-i-Kashmir Institute of Medical Sciences (SKIMS), and informed consent was obtained from all participants.A comprehensive physical/clinical examination was performed in the Department of Medical Oncology, SKIMS, and the patients were evaluated for Jaundice (by examining features like yellowing of eyes and skin), pruritis (by examining features like redness, bumps, spots or blisters, dry/cracked skin and leathery/scaly skin), muscle wasting (by evaluating features like weakness or numbness in the limbs, loss of muscle coordination, tingling or weakness of the extremities, impaired balance while walking, fatigue and a general illness, facial weakness, progressive weakness, gradual memory loss and liver enlargement (were examined by features like abdominal pain, nausea/vomiting, fatigue, whitening of eyes and yellowing of the skin).

    Besides the physical examination, lifestyle activities of the PC patients were also recorded which included smoking status, salt tea consumption, spicy and non-spicy food intake, dried vegetable consumption, mutton, and beef consumption, fish consumption, oil intake, urine habits, bowel habits, and daily physical activity were also recorded.

    Laboratory findings

    The basic clinical laboratory findings were performed by using automated analyzers.The laboratory findings are liver function test (like aspartate transaminase-AST,alanine transaminase-ALT, bilirubin, and alkaline phosphatase-ALP), diabetic status(hyperglycemia) by measuring glucose levels, and anemia by measuring red blood cell(RBC) count.

    Diagnostic imaging

    For any other malignancy PC patients were initially screened by using multiphase multidetector computed tomography (CT) scan, magnetic resonance imaging (MRI),ultrasonography (USG), endoscopic ultrasound (EUS), and chest X-ray (CXR).

    Sample collection

    A total of 5 mL blood sample was collected in clot activator and Ethylenediaminetetraacetic acid (EDTA) vial from PC patients.The serum was separated from the clot activator vials using centrifugation and was stored at -80 °C for further analysis.EDTA vials contain blood was stored at -20 °C for DNA extraction.A tissue chunk (12-50 μm thick tumor tissue section) was obtained from the PC patient by endoscopy using USG-guided probes for mutational analysis and epigenetic modifications.

    Tumor biomarkers

    Tumor markers including CA19-9, TPS, CEA, VEGF-A, and EGFR were estimated in the serum obtained from blood collected from the PC patients.Measurement of CA 19-9, CEA, VEGF-A, and EGFR levels in serum were performed by using a modular E-170 analyzer.However, TPS levels in the serum were measured by using an Immulite instrument.

    Genetic mutation analysis

    Genomic DNA was extracted by the phenol-chloroform method from mononuclear cells.Hypaque density gradient centrifugation was performed to extract leucocytes from blood and tissue samples obtained from PC patients.The quantity and quality control analysis of genomic DNA was performed by carrying out UV spectrophotometer (Eppendorf Biospectrometer?, Hamburg Germany) analysis and Gel electrophoresis, respectively.However, polymerase chain reaction (PCR) was carried out with a different set of primers forKRAS,DPC-4, andBRACA-2genes under different PCR conditions.The PCR products obtained were subjected to Restriction Fragment Length Polymorphism (RFLP) using restriction enzymes BstN1 and BglI for mutational analysis ofKRAScodon 12 and 13, respectively.GGA→TGA in exon 8,codon 358 ofDPC-4gene was analyzed by using MnlI restriction enzyme.6174delT ofBRCA-2was analyzed by using allele-specific PCR technique and polyacrylamide gel electrophoresis (PAGE) was carried out to study any change in theBRCA-2gene.

    Epigenetic analysis

    The epigenetic analysis was performed by examining the methylation status of the promoter and exon regions of genes includingp16,RASSF1A,andhMLH1.The methylation status ofp16,RASSF1A,andhMLH1genes was determined by methylation-specific (MSP) PCR.Briefly, DNA extracted from tissue samples was first subjected to bisulfite conversion using EZ direct methylation kit.The bisulfiteconverted DNA was then subjected to PCR using methylated and unmethylated primers specific for the respective genes.The results were analyzed on 2% agarose gel.

    Statistical analysis

    Numerical data collected from experiments for statistical analysis were performed by using non-parametrical statistical analysis tools which are the Kruskal-Wallis test and Mann-WhitneyUtest.

    RESULTS

    The current study included 50 PC patients with a mean age of 47.82 years at the time of diagnosis for the evaluation of various tumor biological markers for the PC diagnosis.Radio-diagnostics such as USG and CT, confirmed that all 50 patients had PC.Further, histopathological analysis supported the radio-diagnostic results and revealed that out of 50 confirmed PC patients, 47 PC patients had characterized to have adenocarcinoma whereas the remaining 3 PC patients have neuroendocrine carcinoma in the pancreas as shown in Figure 1.The other demographic parameters and daily activities of all confirmed 50 PC patients are presented in Table 1.

    Owing to have relative ease in blood collection and non-invasive, it is preferred to evaluate the biological tumor markers in serum.Therefore, we also intended to evaluate the biological tumor markers which included CA 19-9, TPS, CEA, VEGF-A,and EGFR levels in the blood collected from PC patients.Our results demonstrated that the levels of serum biological tumor markers CA 19-9, CEA, VEGF-A, TPS, EGFR of PC patients were significantly raised in 33 (66%), 32 (64%), 48 (96%), 48 (96%) and 0 out of 50 PC patients, respectively (Table 2) and Figure 2.

    Although the PC progression is a heterogeneous and complex process that includes cell proliferation of intraepithelial and dysplasia to form a mass of cells, followed by an invasion of cells to neighboring tissues.Subsequently, one of the important driving factors of PC progression is genetic mutations of protooncogenes (gain-of-function)and tumor suppressor genes (loss-of-function).Among genetic mutations,KRASmutation is the key point mutation followed by deletion mutation in tumor suppressor genesBRCA-2, DPC-4,andp16in PC.To evaluate whether the PC patients in our study harbor these mutations, we sought to perform mutational analysis ofKRAShotspot codons (codon 12 and codon 13),DPC-4(1203G>T), andBRCA-2mutation(6174delT) in our PC subjects.Our mutational analysis results revealed that out of 50 PC patients, 16 and 12 PC patients hadKRASmutation at codons 12 and 13,respectively.However, we could not find mutation(s) at codons 12 and 13 of theKRASgene in the remaining 34 and 38 PC patients, respectively Figure 3.The representative agarose gel picture of the amplification product of codons 12 and 13 of theKRASgene and their RFLP pattern is shown in Figures 4 and 5.Subsequently, the mutational analysis of tumor suppressor geneDPC-4(1203G>T) andBRCA-2(6174delT) were also evaluated in all PC subjects.Interestingly, we did not find any mutations inDPC-4andBRCA-2mutation at (1203G>T) (6174delT) sites, respectively Figure 3.The representative agarose gel picture ofDPC-4(1203G>T) amplification and RFLP pattern is shown in Figure 6, respectively, and that of amplification and RFLP pattern ofBRCA-2(6174delT) is shown in Figure 7.The results obtained from the genetic mutation analysis are summarized in Table 3.

    Epigenetic alterations have been documented to play a crucial role in PC progression.Thep16, RASSF1A,andhMLH1are key tumor suppressor genes regulating mismatch repair to minimize DNA damage and are frequently inactivated by epigenetic modification in various malignancies.Therefore, we intended to investigate the epigenetic modification (methylation of CpG islands) ofp16, RASSF1A,andhMLH1genes by determining the methylation in their respective promoter regions in all PC subjects.Our epigenetic modification results demonstrated that 21 out of 50 PC subjects were found methylated in the CpG islands of the promoter region of thep16gene while the remaining 29 were unmethylated.However, the CpG islands in the promoter region ofRASSF1Awere found to be unmethylated in all 50 PC patients.Additionally, we observed that 4 out of 50 PC patients showed methylation patterns in the promoter region of thehMLH1gene, whereas the remaining 46 PC patients had thehMLH1gene unmethylated in their promoter regions.The representative agarose gel pic of MS-PCR forhMLH1andRASSF1Ais shown in Figure 8.The methylation and unmethylation status as observed in the present study forp16, hMLH1,andRASSF1Aare summarized in Table 4 and Figure 9.

    Figure 1 Distribution of samples (cases) based on subtypes of pancreatic cancer.PC: Pancreatic cancer.

    Figure 2 Analysis of tumor biological marker (carbohydrate antigen 19-9, tissue polypeptide specific antigen, carcinoembryonic antigen,vascular endothelial growth factor-A, and epidermal growth factor receptor) in the serum of pancreatic cancer patients.PC: Pancreatic cancer; CA19-9: Carbohydrate antigen 19-9; TPS: Tissue polypeptide specific antigen; CEA: Carcinoembryonic antigen; VEGF-A: Vascular endothelial growth factor-A; EGFR: Epidermal growth factor receptor.

    Figure 3 MutationaI anaIysis of KRAS (Codon 12 and 13), DPC-4, and BRCA-2 gene mutations within pancreatic cancer cases.KRAS:Kirsten rat sarcoma; DPC-4: Deleted in pancreatic cancer-4; BRCA-2: Breast cancer type 2.

    Figure 4 Representative agarose geI picture of poIymerase chain reaction ampIification (A) and restriction fragment Iength poIymorphism using BstN1 (B) for KRAS codon 12.The arrow represents the 157 bp amplicon and M denotes the DNA marker (50 bp).Lane M represents a DNA marker(50 bp).Lanes 2, 4, 7, 8, and 10 represent the mutant band (undigested) of 157 bp.Lane 1, 3, 6, and 9 represent the wild band (digested) of 128 bp.U represents the undigested band used as mutant control.

    Figure 5 Representative geI picture of poIymerase chain reaction ampIification (A) and restriction fragment Iength poIymorphism using BgII (B) for K-RAS codon 13.The arrow represents the 157 bp amplicon and M denotes the DNA marker (100 bp).Lane M represents a DNA marker (100 bp).Lanes 2, 3, 6, 7, 8, 9, 10, and 11 represent the mutant band (undigested) of 157 bp.Lanes 1, 4, 5, and 8 represent a wild band (digested) of 125 bp.

    Figure 6 Representative geI picture of poIymerase chain reaction ampIification and restriction fragment Iength poIymorphism using MnII of DPC-4.The arrow represents the 184bp amplicon and M denotes the DNA marker (100 bp).Lane M represents a DNA marker (50 bp).117 bp and 67 bp represent the wild bands (digested).U represents the mutant control band of 184 bp (undigested).

    Figure 7 Representative agarose geI picture of AS-poIymerase chain reaction ampIification (A) and geI picture representing poIyacryIamide geI eIectrophoresis (20% geI) (B) of BRCA-2.All the lanes show 151 bp amplicon which is the wild band and M denotes the DNA marker(100 bp).M is the marker lane (25 bp).Here also, the only wild band (151 bp) is observed in all the lanes.

    Figure 8 GeI picture representing MS-poIymerase chain reaction for hMLH1 (A, 100 bp) and RASSF1A (B, 25 bp).M represents DNA marker;UMC represents unmethylated control; MC represents methylated control; NM represents normal methylated; NUM represents normal unmethylated; TUM represents tumor unmethylated; TM represents tumor methylation.

    Figure 9 Methylation and unmethylation status in the promoter region of p16, RASSF1A, and hMLH1 within pancreatic cancer subjects.PC: Pancreatic cancer.

    Table 1 Characteristics and clinical presentations of cases in the present study, n (%)

    Table 2 Analysis of tumor biological marker in the serum of pancreatic cancer patients

    Table 3 Mutational analysis of KRAS (Codon 12 and 13), DPC-4, and BRCA-2 gene mutations within pancreatic cancer subjects

    Table 4 Methylation and unmethylation status in the promoter region of p16, RASSF1A, and hMLH1within pancreatic cancer subjects

    DISCUSSION

    Despite new therapeutic approaches to improve the outcome of PC patients by the introduction of molecular target approaches and combinatorial therapy, there is an unmet need to find the prospective biomarkers for early diagnosis of PC[27].Therefore, the aim of the current study was to collective evaluation of tumor biological markers, mutational status, and epigenetic modulations in PC patients of the ethnic Kashmiri population for early diagnosis.Our findings revealed the elevated levels of serum biomarkers CA 19-9, TPS, CEA, and VEGF-A, in the blood samples of PC patients, however, EGFR levels were found to be in the normal range.The mutational analysis demonstrated that theKRASgene mutation which is the major driver in PC progression was found in codons 12 (16 subjects) and 13 (12 subjects).Furthermore,DNA of CpG islands of 21 subjects was found significantly methylated in the promoter regions of thep16gene.Collectively, these results suggest that in combination with mutational analysis and epigenetic modulations (CpG methylation), the biologicaltumor markers evaluated in PC subjects could be valuable for early diagnostics and could strongly predict the PC prognostics.Additionally, these types of studies could further strengthen the validation of biological tumor markers and have a promising perspective for the predisposition and susceptibility towards PC.

    A biological tumor marker is an entity in the body that gives information about a diagnosis, prognosis, and therapeutic modalities for a particular disease.The preferred entity to be eligible as a biomarker should be available in body fluids and non-invasive[28].One of the important tumor biomarkers used in various malignancies is a high molecular weight glycoprotein CA 19-9.Biochemically, a carbohydrate antigen, CA19-9 is mainly expressed by the cells of the pancreaticobiliary system.Previous studies suggest that CA 19-9 levels were elevated in gut-associated malignancies such as gastric, bile duct, colorectal, and ovarian cancers.Owing to its relatively higher sensitivity and specificity among other biomarkers in PC patients, CA 19-9 is an important and valuable biomarker in the diagnostics of PC[29].Although reports suggest a significant progress in overall survival and reduction in CA19-9 levels in PC,however, a recent study by Hesset al[30] did not support these findings.O’Brienet al[31] reported that CA 19-9 levels were raised in PC patients and may act as a better biomarker for the early diagnosis of PC.Besides, the levels of CA 19-9 were found directly associated with tumor size, tumor burden, and stage of tumorigenesis in PC,the pre-and post-operative levels of CA 19-9 in PC patients could be used as a prognosticator.Consistent with these findings, our results revealed that out of 50 PC patients 33 had significantly elevated levels of CA 19-9 in their blood samples, which indicates that more studies with a large cohort size are needed in the future to validate CA 19-9 as a better early diagnostic biomarker in PC.

    Another valuable biomarker used in the diagnosis of various malignancies is TPS.It is essentially an antigen that binds to the epitope of soluble cytokeratin 18 fragments.The striking feature of TPS is to differentiate between PC and chronic pancreatitis and it is a better marker than CA 19-9 for differentiating PC and pancreatitis[32].Previous studies suggested that serum TPS levels have a better correlation with gastric,colorectal, and pancreatic cancer than CA 19-9, CA 195, or CEA biomarkers[33,34].Consistent with the previous studies, our results revealed that 48 out of 50 confirmed PC patients had significantly elevated levels of TPS, which suggests that elevated levels of serum TPS are better correlated with PC than CA 19-9 and could act as a better diagnostic and prognostic biomarker in PC.CEA, a glycoprotein, first identified in 1965, is present normally in the fetal pancreas, gastrointestinal tract, and liver.In the adolescent stage, it is found in lesser quantity in endodermal tissue and colon.CEA was used as a diagnostic marker of PC decades before and is now replaced by markers that have greater sensitivity for the detection of PC[35].Elevated serum levels of CEA have been documented in more than 60% of cases of PC.Consistent with previous findings, our results demonstrated that 64% of patients (32 out of 50 confirmed PC)had elevated levels of serum CEA.However, if used with other biomarkers for early diagnostics, CEA could be adding up great value to early diagnostics of PC[36].High expression of VEGF-A is associated with tumor size and progression.Overexpression of VEGF-A has been reported in head and neck, non-small cell lung, ovarian,endometrial, osteosarcoma, bladder, B cell lymphoma, ocular adnexal lymphoma,papillary renal cell carcinoma, and pancreatic cancers.VEGF-A is reported to have an 80 gene loci whose alterations are reported in hepatocarcinoma, lung, pancreatic, and endometrial cancers[36].A study conducted by Seoet al[37] demonstrated that 93% of ductal pancreatic adenocarcinomas showed high expression of VEGF-A protein.In the recent past, around 77% of VEGF-A expression was observed in PC tissues whereas only 15% of VEGF-A expression was found in the normal range[38].Consistent with these findings, our results showed that out of 50 confirmed PC subjects, 48 cases had elevated levels of VEGF-A expression, which indicates that VEGF-A plays a critical role and had a strong causal association with PC progression, thus could act as a valuable tumor biomarker in combination with other biomarkers for early diagnosis of PC.

    Besides, the currently available biomarkers for PC diagnostics, it is worthy to introduce genetic markers to develop more sophisticated tools for early detection of PC.PC is a disease that harbors somatic as well as hereditary mutations.Approximately, 5%-10% of the familial PC is caused by a mutation in a myriad of genes and surges the predisposition to PC by several-fold[24].Previous studies reported that several genes showed a strong causal association with PC progression, among these most important areKRAS, DPC-4,andBRCA-2which in turn are associated with different other genes using different interactions like physical interaction, genetic interaction, shared protein interaction,etc.as depicted in Figure 10[39].The most common mutation reported in PC isKRASmutation and is the earliest recognizable event in its pathogenesis.Studies have reported that mutations in theKRASgene are mainly limited to codon 12 and rarely on codon 13[40,41].The pathological mutation inKRASencodes constitutive Ras protein which belongs to GTP binding protein family.The constitute Ras protein facilitates the oncogenic signaling pathway which leads to inflammation, deregulated cellular growth, cell motility, and remodeling of the cytoskeletal elements.KRASgene mutations are known to be driver mutations that occur sporadically.It accounts for 30% of early neoplasms of the pancreas and nearly 100% in pancreatic adenocarcinomas.Besides PC, a mutation in theKRASgene is adequate to promote lung cancer, colon cancer, breast cancer, and other cancers as well[42,43].Recent clinical data suggest thatKRASmutations act as significant prognostic biomarker to predict therapeutic intervention for PC management.Kimet al[44]demonstrated that out of 136 PC patients, 70 PC patients harbored point mutation in codon 12 of theKRASgene, and these patients have shown dismal response to gemcitabine-based chemotherapy compared to those who had wild type allele forKRASgene[44].Another study revealed that out of 173 PC patients, 121 were found to harbor point mutations in codon 12 of theKRASgene, and among them are nonresponders to erlotinib.However, patients with wild-type alleles displayed a promising overall survival rate[45].Consistent with these studies, our mutational analysis results revealed that 16 PC patients hadKRASpoint mutation at codon 12,interestingly we observe point mutation in theKRASgene at codon 13.These findings suggest that further studies are needed to validate the high frequency of point mutation in codon 13 of theKRAS gene.BRCA-1 and BRCA-2germline mutations substantially increase the lifetime risk of breast cancer tumorigenesis.Recent reports suggest that the mutations in these genes also have a strong causal association with other cancers including PC[46].The primary role of theBRCA-2gene is the maintenance of the genome by enhancing homologous recombination of a doublestranded break.Approximately, 80% ofBRCA-2mutations are either frameshift or non-sense mutations which result in the formation of premature stop codons to encode non-functional BRCA-2 protein.BRCA-2mutations have been found in 7.3% of familial PC patients which indicates an increased risk of cancers by about 20-fold[47].DPC-4(SMAD-4)is a tumor suppressor gene intricated in the regulatory mechanisms of gene transcription.Approximately, 30% of PC cases have been reported to harbor homozygous mutations in theDPC-4gene[21].The mutatedDPC-4gene-encoded hyperactivated Smad-4 protein leads to the activation of TGF-β pathways thereby promote cell proliferation and tumor growth.Mutations in theDPC-4gene have been reported in approximately 50% of PCs and serves as a leading cause of protein inactivation[48].Inconsistent with previous studies, our mutational analysis ofBRCA-2andDPC-4genes revealed a zero frequency ofDPC-41203 G>T andBRCA-26174 deletion in PC patients.Collectively, these findings suggest that a larger sample size is needed to validate our results in the ethnic Kashmiri population.

    Figure 10 Interaction of KRAS, SMAD4 (DPC4), and BRCA2 with other genes based on various parameters.KRAS: Kirsten rat sarcoma; DPC-4:Deleted in pancreatic cancer-4; BRCA-2: Breast cancer type 2.

    Epigenetic modulations play a critical role in tumorigenesis.Change in DNA methylation of tumor suppressor genes has indispensable importance in therapeutics and could serve as biomarkers for diagnostics and prognostics in various cancers[49].p16is a tumor suppressor gene that encodes cyclin-dependent kinase inhibitors to arrest the cellular growth of malignant cells.Besides point mutations and homozygous deletions in thep16gene, recent evidence suggests that methylation of CpG islands in the promoter regions ofp16stimulates transcriptional silencing of thep16gene and contributes to PC progression.In the recent past, hypermethylation in the promoter region ofp16is significantly raised in chronic pancreatitis compared to normal;suggesting that hypermethylation in the promoter region of thep16gene might deregulate cell cycle kinetics and could promote PC progression.Further, reports demonstrated thatp16hypermethylation in chronic pancreatitis might increase the risk of PC development many-fold[48].Mooreet al[50] demonstrated the role ofp16promoter hypermethylation and associated molecular pathways involved in exocrine and endocrine development of PC.Further, studies suggest that the reduction in overall survival rate associated withp16alterations signifies the fact thatp16could act as an important diagnostic and prognostic biomarker in resected ductal PC patients[51].RASSF1Ais another tumor suppressor and an important component of RAS/PI3K/AKT and RAS/RAF/MEK/ERK pathways that have been epigenetically inactivated in various sporadic human malignancies.A higher frequency of promoter methylation status ofRASSF1Ahas been implicated in several cancers.The highest frequency ofRASSF1Apromoter hypermethylation was reported in prostate cancer(99%), followed by lung cancer (95%) and breast cancer (88%)[52].Recent reports suggest that a low frequency ofhMLH1hypermethylation was detected in PC.The loss of thehMLH1gene which encodes for Mut L protein homology 1 is common in various cancers.Further, whole-genome sequencing revealed that somatichMLH1mutations are rare in cancers with an observed frequency of < 1%[53].In the present study, we carried out epigenetic modifications (CpG methylation) of promoter regions ofp16,RASSF1A,andhMLH1genes.Our results demonstrate that significant hypermethylation (CpG islands) was reported in the promoter regions of thep16gene in PC patients.However, we observed an extremely low frequency of methylation in the promoter region of thehMLH1gene in PC patients.Interestingly, the CpG methylation in the promoter region of theRASSF1Agene was completely absent in PC patients.Additionally,in-silicoanalysis suggest that plethora of genes are associated through various interactions with the key genes (hMLH1,RASSF1A, andCDKN2A) as in Figure 11, which could play a key role in the progression of PC[39].Together, these results suggest that a cohort and comprehensive study with larger sample size is needed to document our findings in the ethnic Kashmiri population.

    Figure 11 Interaction of MLH1, RASSF1, and CDKN2A (p16) with other important genes which have a role in the progression of pancreatic cancer.

    CONCLUSION

    In conclusion, the present study strongly suggests that the elevated levels of serum CA 19-9, TPS, CEA, and VEGF-A can be used as predictive biomarkers in PC patients of the ethnic Kashmiri population and may act as prognostic biomarkers to benefit the patients who are on a different regimen of chemotherapeutic interventions.Further,mutational analysis data suggest that besides harboring point mutation in codon 12 ofKRASgene, the PC patients of the current study significantly harbored codon 13-point mutation as well, which is very rarely reported in the previous studies.This may act as a genetic risk predictor in the development of PC.Additionally, considerable hypermethylation (CpG islands) in the promoter region of thep16gene in the current study may lead to silencing of thep16gene and could also increase the predisposition towards PC.However, we could not find the association ofDPC-4G>T andBRCA-26174 deletion mutations and hypermethylation of CpG islands in the promoter region ofRASSF1AandhMLH1gene towards the risk of PC.To validate these results in the Kashmiri population the future studies need to be comprehensive and with larger sample sizes.

    ARTICLE HIGHLIGHTS

    Research background

    Pancreatic cancer (PC) is one of the deadliest malignancies with an alarming mortality rate.Despite significant advancement in diagnostics and therapeutics, early diagnosis remains elusive causing poor prognosis, marred by mutations and epigenetic modifications in key genes which contribute to disease progression.

    Research motivation

    To explore the various biological tumor markers collectively and mutational analysis of key regulatory genes for early diagnosis and prognosis of PC.

    Research objectives

    To evaluate various biological tumor markers collectively in PC and their association with genetic mutation and epigenetic modification of key regulatory genes that could act as early diagnostic and prognostic biomarkers and will help in future therapeutics of PC in Kashmir valley.

    Research methods

    The current study includes 50 confirmed PC cases to evaluate the levels of carbohydrate antigen 19-9 (CA 19-9), tissue polypeptide specific antigen (TPS),carcinoembryonic antigen (CEA), vascular endothelial growth factor-A (VEGF-A), and epidermal growth factor receptor (EGFR) by enzyme-linked immunosorbent assay(ELISA) method.Mutational analysis of key genes Kirsten rat sarcoma (KRAS), Breast cancer type 2 (BRCA-2), and deleted in pancreatic cancer-4 (DPC-4) genes was performed to evaluate the mutations at hotspot regions.Furthermore, epigenetic modifications were performed in the promoter regions of cyclin-dependent kinase inhibitor 2A (p16; CDKN2A), MutL homolog 1 (hMLH1), and Ras association domaincontaining protein 1 (RASSF1A) genes.

    Research results

    Besides significant elevation in levels of tumor markers CA 19-9 (P ≤0.05), TPS (P ≤0.05), CEA (P ≤0.001), and VEGF (P ≤0.001), our mutational analysis observed thatKRASgene mutation is predominant in codon 12 (16 subjects,P ≤0.05), and 13 (12 subjects,P ≤0.05).Additionally, epigenetic modification analysis suggests that CpG methylation was observed in 21 (P ≤0.05) and 4 subjects in the promoter regions of thep16andhMLH1gene, respectively.

    Research conclusions

    The study revealed the significant elevation of serum biological markers in PC patients and the causal association of hotspot mutations and epigenetic modification of key with PC pathogenesis thus indicates the potential of biological markers, mutational status, and epigenetic modifications of key genes collectively for predisposition,susceptibility as well as diagnostics and prognostics of PC.

    Research perspectives

    The study strongly suggests that the elevated levels of serum CA 19-9, TPS, CEA, and VEGF-A can be used as predictive biomarkers in PC subjects.Additionally, mutational analysis epigenetic modifications in the promoter region of key genes may act as prognostic biomarkers to benefit the patients who are on a different regimen of chemotherapeutic interventions.Further to validate these results, future studies need comprehensive, cohort, and explicative studies with large sample sizes.

    ACKNOWLEDGEMENTS

    The authors extend their appreciation to the State Department of Science and Technology, Jammu and Kashmir, India.

    国产极品精品免费视频能看的| 亚洲电影在线观看av| 国产熟女xx| 91在线观看av| 熟妇人妻久久中文字幕3abv| 欧美日韩综合久久久久久 | 老司机福利观看| 欧美国产日韩亚洲一区| 无人区码免费观看不卡| 亚洲不卡免费看| 久久久久久国产a免费观看| 国产精品,欧美在线| 不卡一级毛片| 欧美日韩国产亚洲二区| 久久精品国产99精品国产亚洲性色| 啪啪无遮挡十八禁网站| 国产高清视频在线播放一区| 亚洲成人免费电影在线观看| 亚洲av成人精品一区久久| 亚洲av免费高清在线观看| 男女之事视频高清在线观看| 老汉色av国产亚洲站长工具| 少妇人妻一区二区三区视频| 可以在线观看毛片的网站| 午夜福利成人在线免费观看| 好男人在线观看高清免费视频| 18禁在线播放成人免费| 美女高潮喷水抽搐中文字幕| 99国产综合亚洲精品| 色播亚洲综合网| 麻豆国产av国片精品| 久久久国产成人精品二区| 中文在线观看免费www的网站| 午夜视频国产福利| 国产一级毛片七仙女欲春2| 人人妻人人澡欧美一区二区| 日本精品一区二区三区蜜桃| 亚洲av熟女| 免费大片18禁| 成人性生交大片免费视频hd| 精品人妻一区二区三区麻豆 | 免费观看的影片在线观看| 国产麻豆成人av免费视频| 亚洲av不卡在线观看| 麻豆国产av国片精品| 精品欧美国产一区二区三| 精品一区二区三区视频在线 | 在线天堂最新版资源| 午夜两性在线视频| 亚洲精品成人久久久久久| 亚洲精品色激情综合| 一进一出好大好爽视频| 99精品欧美一区二区三区四区| 国内毛片毛片毛片毛片毛片| 国产成人av教育| 少妇的丰满在线观看| 欧美一级a爱片免费观看看| 欧美日本视频| 欧美+亚洲+日韩+国产| www日本黄色视频网| 亚洲激情在线av| 黄色视频,在线免费观看| 午夜福利视频1000在线观看| 国产伦精品一区二区三区四那| 成人av一区二区三区在线看| 亚洲国产欧美人成| 成年免费大片在线观看| 国语自产精品视频在线第100页| 最新中文字幕久久久久| a在线观看视频网站| 男女那种视频在线观看| 日本免费一区二区三区高清不卡| 国产精品自产拍在线观看55亚洲| 亚洲欧美精品综合久久99| 99热这里只有是精品50| 熟女电影av网| av中文乱码字幕在线| 大型黄色视频在线免费观看| 久久精品国产亚洲av香蕉五月| 久久香蕉国产精品| 男女之事视频高清在线观看| 日本免费a在线| 最后的刺客免费高清国语| 国内精品久久久久久久电影| 国产 一区 欧美 日韩| 国产精品野战在线观看| 国产一区二区三区视频了| 日韩欧美国产一区二区入口| 九九久久精品国产亚洲av麻豆| 国产一区二区激情短视频| 我要搜黄色片| 国产成人影院久久av| 最新在线观看一区二区三区| 久久久久精品国产欧美久久久| 亚洲国产欧美网| 少妇高潮的动态图| 亚洲狠狠婷婷综合久久图片| 精品一区二区三区人妻视频| 国内揄拍国产精品人妻在线| 我要搜黄色片| 国产精品 国内视频| 亚洲人与动物交配视频| 欧美一级a爱片免费观看看| 一个人看的www免费观看视频| 免费看a级黄色片| 成人国产一区最新在线观看| 久久久久久久久久黄片| 禁无遮挡网站| 精品久久久久久成人av| 欧美精品啪啪一区二区三区| 熟女电影av网| 色吧在线观看| 亚洲精品久久国产高清桃花| 成人亚洲精品av一区二区| 国产伦精品一区二区三区四那| 亚洲中文字幕日韩| 午夜免费观看网址| 母亲3免费完整高清在线观看| 欧美色欧美亚洲另类二区| 亚洲成a人片在线一区二区| 午夜激情福利司机影院| 国产色婷婷99| 欧美日韩精品网址| 在线观看一区二区三区| 女人十人毛片免费观看3o分钟| 国产中年淑女户外野战色| 久久人妻av系列| 少妇高潮的动态图| 男女做爰动态图高潮gif福利片| 丰满乱子伦码专区| 熟女人妻精品中文字幕| 真实男女啪啪啪动态图| h日本视频在线播放| 国产乱人伦免费视频| 91字幕亚洲| 岛国视频午夜一区免费看| 中亚洲国语对白在线视频| 一本久久中文字幕| 天堂网av新在线| 精品福利观看| 国产精品av视频在线免费观看| 日本a在线网址| x7x7x7水蜜桃| 特级一级黄色大片| 亚洲国产精品sss在线观看| 免费看美女性在线毛片视频| 在线看三级毛片| 免费一级毛片在线播放高清视频| 精品人妻偷拍中文字幕| 久久这里只有精品中国| 欧美zozozo另类| 夜夜夜夜夜久久久久| 国产av麻豆久久久久久久| 午夜福利在线观看免费完整高清在 | 丰满的人妻完整版| 黄片大片在线免费观看| 国产高清三级在线| 国产午夜福利久久久久久| 少妇丰满av| 在线观看美女被高潮喷水网站 | 色在线成人网| 精品久久久久久久毛片微露脸| 国产淫片久久久久久久久 | 欧美成人性av电影在线观看| www国产在线视频色| 国产成人a区在线观看| 国产亚洲精品久久久久久毛片| 欧美bdsm另类| 亚洲五月天丁香| 成年女人毛片免费观看观看9| 99久久精品一区二区三区| 999久久久精品免费观看国产| www.色视频.com| 91久久精品国产一区二区成人 | 90打野战视频偷拍视频| 久久久久性生活片| 亚洲男人的天堂狠狠| 久久久久国产精品人妻aⅴ院| 亚洲乱码一区二区免费版| 19禁男女啪啪无遮挡网站| 国产成人影院久久av| 日韩欧美国产在线观看| 我的老师免费观看完整版| 97超视频在线观看视频| 别揉我奶头~嗯~啊~动态视频| 美女高潮的动态| 中文字幕高清在线视频| 麻豆久久精品国产亚洲av| 日韩欧美三级三区| 99在线视频只有这里精品首页| 午夜久久久久精精品| 久久国产精品影院| 精品国产美女av久久久久小说| 成人无遮挡网站| 欧美国产日韩亚洲一区| 国产av不卡久久| 日韩欧美免费精品| 怎么达到女性高潮| 国内揄拍国产精品人妻在线| 在线观看免费午夜福利视频| 亚洲成人免费电影在线观看| 69av精品久久久久久| 国产激情欧美一区二区| 91字幕亚洲| 国产一区二区激情短视频| 亚洲欧美精品综合久久99| 国产精品亚洲美女久久久| 97人妻精品一区二区三区麻豆| 高清毛片免费观看视频网站| 国产成+人综合+亚洲专区| 久久精品国产清高在天天线| 又爽又黄无遮挡网站| 欧美日韩黄片免| 偷拍熟女少妇极品色| 操出白浆在线播放| 一本精品99久久精品77| 欧美成人a在线观看| 好男人在线观看高清免费视频| 免费一级毛片在线播放高清视频| 亚洲精品一区av在线观看| 俄罗斯特黄特色一大片| www国产在线视频色| 小说图片视频综合网站| 欧美在线黄色| 亚洲欧美一区二区三区黑人| 99热6这里只有精品| 欧美+日韩+精品| 免费看a级黄色片| 免费大片18禁| 久久草成人影院| 欧美绝顶高潮抽搐喷水| 久久人人精品亚洲av| 黄色视频,在线免费观看| 国产97色在线日韩免费| 国产亚洲精品一区二区www| 亚洲美女黄片视频| 香蕉丝袜av| 亚洲欧美精品综合久久99| 亚洲av五月六月丁香网| 国产伦精品一区二区三区视频9 | 精品久久久久久成人av| 日韩成人在线观看一区二区三区| 欧美日韩福利视频一区二区| 亚洲中文字幕日韩| 亚洲aⅴ乱码一区二区在线播放| 日日夜夜操网爽| 男女下面进入的视频免费午夜| 欧美日韩一级在线毛片| 三级男女做爰猛烈吃奶摸视频| 一个人免费在线观看的高清视频| 黑人欧美特级aaaaaa片| 免费av毛片视频| e午夜精品久久久久久久| 成人特级黄色片久久久久久久| 我要搜黄色片| 中文资源天堂在线| 亚洲国产欧美人成| 欧美最黄视频在线播放免费| 国产午夜精品久久久久久一区二区三区 | 每晚都被弄得嗷嗷叫到高潮| 亚洲成人精品中文字幕电影| 少妇裸体淫交视频免费看高清| 国产精品亚洲av一区麻豆| 两性午夜刺激爽爽歪歪视频在线观看| 啦啦啦免费观看视频1| 日韩av在线大香蕉| 最新美女视频免费是黄的| 欧美三级亚洲精品| 久久精品影院6| aaaaa片日本免费| 日韩精品中文字幕看吧| 一区福利在线观看| 久久天躁狠狠躁夜夜2o2o| 日本一本二区三区精品| av欧美777| 桃色一区二区三区在线观看| 国产乱人视频| 一本一本综合久久| 在线观看66精品国产| 日韩欧美免费精品| 少妇的逼水好多| 美女黄网站色视频| 成人18禁在线播放| 91av网一区二区| 国产亚洲av嫩草精品影院| 欧美日韩精品网址| 两个人视频免费观看高清| 亚洲成av人片在线播放无| 久久久久久久久大av| 欧美一级毛片孕妇| 国产野战对白在线观看| 成人无遮挡网站| 欧美激情久久久久久爽电影| 欧美性猛交╳xxx乱大交人| 淫妇啪啪啪对白视频| 男女下面进入的视频免费午夜| 成年免费大片在线观看| 亚洲av成人不卡在线观看播放网| 午夜精品久久久久久毛片777| 久久香蕉精品热| 久久亚洲真实| 国产毛片a区久久久久| 国产精品三级大全| 国产精品一区二区免费欧美| 他把我摸到了高潮在线观看| 内地一区二区视频在线| 精华霜和精华液先用哪个| 欧美色视频一区免费| 一级黄色大片毛片| 午夜老司机福利剧场| 在线十欧美十亚洲十日本专区| 90打野战视频偷拍视频| 免费av观看视频| 亚洲国产欧美人成| 成人精品一区二区免费| 国产一区二区亚洲精品在线观看| 啦啦啦观看免费观看视频高清| 国产蜜桃级精品一区二区三区| 人妻久久中文字幕网| 日韩精品青青久久久久久| 久久久久九九精品影院| 老司机在亚洲福利影院| 91久久精品国产一区二区成人 | 国产精品三级大全| 人妻丰满熟妇av一区二区三区| 日韩欧美一区二区三区在线观看| 成熟少妇高潮喷水视频| 少妇人妻一区二区三区视频| 中出人妻视频一区二区| 美女大奶头视频| 欧美黄色淫秽网站| 日韩精品青青久久久久久| 成人性生交大片免费视频hd| 国产乱人视频| 精品无人区乱码1区二区| 两个人的视频大全免费| 99在线视频只有这里精品首页| 精品国产亚洲在线| 99在线视频只有这里精品首页| 午夜福利在线观看免费完整高清在 | 欧美日韩一级在线毛片| 日韩人妻高清精品专区| 国产精品美女特级片免费视频播放器| 久久久久久人人人人人| 午夜激情欧美在线| 最好的美女福利视频网| xxxwww97欧美| 色在线成人网| 欧美成人免费av一区二区三区| 国产三级在线视频| 成人鲁丝片一二三区免费| 人人妻人人澡欧美一区二区| 夜夜夜夜夜久久久久| 人人妻人人澡欧美一区二区| 成年免费大片在线观看| 精华霜和精华液先用哪个| 亚洲第一欧美日韩一区二区三区| 日韩 欧美 亚洲 中文字幕| 女人被狂操c到高潮| 女人高潮潮喷娇喘18禁视频| 狂野欧美激情性xxxx| 国产成人系列免费观看| 亚洲男人的天堂狠狠| 一区福利在线观看| 午夜久久久久精精品| 久久精品国产清高在天天线| 亚洲在线自拍视频| 国产精品三级大全| 亚洲国产日韩欧美精品在线观看 | 欧美不卡视频在线免费观看| 免费人成视频x8x8入口观看| 婷婷精品国产亚洲av| 国产精品久久久久久人妻精品电影| 国产精品乱码一区二三区的特点| 欧美激情在线99| 国内精品一区二区在线观看| 色精品久久人妻99蜜桃| 成年女人看的毛片在线观看| 一级作爱视频免费观看| 嫩草影视91久久| 三级毛片av免费| 午夜福利在线在线| 亚洲一区高清亚洲精品| avwww免费| 精品久久久久久成人av| 色吧在线观看| 国产激情欧美一区二区| 亚洲性夜色夜夜综合| 国产亚洲精品av在线| 天天添夜夜摸| www日本在线高清视频| 91在线精品国自产拍蜜月 | 男人和女人高潮做爰伦理| 在线天堂最新版资源| 久久九九热精品免费| 每晚都被弄得嗷嗷叫到高潮| 亚洲人成伊人成综合网2020| 色在线成人网| 欧洲精品卡2卡3卡4卡5卡区| 亚洲,欧美精品.| 中文字幕久久专区| 色综合站精品国产| 国产午夜精品论理片| 18禁美女被吸乳视频| 亚洲av五月六月丁香网| 日本一二三区视频观看| av在线蜜桃| 51国产日韩欧美| 日韩欧美国产一区二区入口| 国产v大片淫在线免费观看| avwww免费| 国产在视频线在精品| 岛国视频午夜一区免费看| 精品国内亚洲2022精品成人| 女生性感内裤真人,穿戴方法视频| 人人妻人人看人人澡| 国产精品女同一区二区软件 | 欧美乱码精品一区二区三区| 欧美激情在线99| 在线a可以看的网站| 给我免费播放毛片高清在线观看| 国产精品综合久久久久久久免费| 国内精品久久久久久久电影| 国产一区二区在线观看日韩 | 欧美在线黄色| 制服人妻中文乱码| 成年女人永久免费观看视频| 香蕉久久夜色| 日韩av在线大香蕉| 久久精品91蜜桃| 俺也久久电影网| 757午夜福利合集在线观看| 俄罗斯特黄特色一大片| 啦啦啦韩国在线观看视频| 无遮挡黄片免费观看| 男插女下体视频免费在线播放| 内射极品少妇av片p| 久久久久久久午夜电影| 精品一区二区三区av网在线观看| 亚洲精品日韩av片在线观看 | netflix在线观看网站| 日本精品一区二区三区蜜桃| 在线播放国产精品三级| 国产成人系列免费观看| 国产日本99.免费观看| 1000部很黄的大片| 免费看十八禁软件| 少妇高潮的动态图| 国产精品女同一区二区软件 | 精品欧美国产一区二区三| 国产精品1区2区在线观看.| 免费大片18禁| 亚洲午夜理论影院| 久久香蕉国产精品| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 此物有八面人人有两片| 97超级碰碰碰精品色视频在线观看| 精品人妻1区二区| 精品午夜福利视频在线观看一区| 国产精品免费一区二区三区在线| a级一级毛片免费在线观看| 乱人视频在线观看| 中文字幕高清在线视频| 亚洲欧美日韩卡通动漫| 国产一级毛片七仙女欲春2| 麻豆成人午夜福利视频| 日本与韩国留学比较| 内地一区二区视频在线| 国产国拍精品亚洲av在线观看 | 成人三级黄色视频| 久久久久精品国产欧美久久久| 哪里可以看免费的av片| 老司机深夜福利视频在线观看| 免费人成视频x8x8入口观看| 国产免费一级a男人的天堂| 两人在一起打扑克的视频| 啦啦啦免费观看视频1| 观看免费一级毛片| 欧美日韩中文字幕国产精品一区二区三区| 香蕉久久夜色| 国产成人影院久久av| 伊人久久大香线蕉亚洲五| 特大巨黑吊av在线直播| 天堂动漫精品| 搞女人的毛片| 给我免费播放毛片高清在线观看| 国产野战对白在线观看| 国产综合懂色| 乱人视频在线观看| 小说图片视频综合网站| 精品无人区乱码1区二区| 国产精品香港三级国产av潘金莲| 亚洲在线自拍视频| 免费大片18禁| 一区二区三区激情视频| 成年免费大片在线观看| 国产91精品成人一区二区三区| 一级毛片高清免费大全| av视频在线观看入口| 国产极品精品免费视频能看的| av片东京热男人的天堂| www.色视频.com| 小蜜桃在线观看免费完整版高清| av视频在线观看入口| 不卡一级毛片| 国产精品久久久久久久久免 | 最近视频中文字幕2019在线8| www日本在线高清视频| 久久午夜亚洲精品久久| 亚洲自拍偷在线| 久久久久精品国产欧美久久久| 丰满乱子伦码专区| 国产精品1区2区在线观看.| 国产精品美女特级片免费视频播放器| 色噜噜av男人的天堂激情| 国产成人a区在线观看| 超碰av人人做人人爽久久 | 啪啪无遮挡十八禁网站| 精品人妻偷拍中文字幕| 亚洲精品乱码久久久v下载方式 | 久久久久国产精品人妻aⅴ院| 亚洲av免费高清在线观看| 亚洲真实伦在线观看| 日韩欧美国产在线观看| 国产精品精品国产色婷婷| 亚洲精品一卡2卡三卡4卡5卡| 黄色片一级片一级黄色片| 热99在线观看视频| 少妇的逼水好多| 久久天躁狠狠躁夜夜2o2o| 97碰自拍视频| 精品人妻一区二区三区麻豆 | 丁香六月欧美| 日本免费a在线| 国产毛片a区久久久久| 天天躁日日操中文字幕| 一区二区三区高清视频在线| 99久久综合精品五月天人人| 精品国产美女av久久久久小说| 亚洲人成网站高清观看| 国产一区二区亚洲精品在线观看| 国语自产精品视频在线第100页| 狂野欧美白嫩少妇大欣赏| 男女下面进入的视频免费午夜| 日日摸夜夜添夜夜添小说| 一个人观看的视频www高清免费观看| 麻豆久久精品国产亚洲av| 人妻久久中文字幕网| 国产一区二区在线av高清观看| 亚洲色图av天堂| 三级毛片av免费| 久久久久久久久大av| 搡老熟女国产l中国老女人| 久久久久国内视频| 亚洲成人精品中文字幕电影| 亚洲欧美日韩高清在线视频| 99国产精品一区二区蜜桃av| 一区二区三区高清视频在线| 日韩欧美在线二视频| or卡值多少钱| 精品国产亚洲在线| 精品午夜福利视频在线观看一区| 女生性感内裤真人,穿戴方法视频| 亚洲av二区三区四区| 亚洲欧美激情综合另类| 岛国视频午夜一区免费看| 国产精品乱码一区二三区的特点| 欧美日韩一级在线毛片| 99久久精品热视频| 国产亚洲精品一区二区www| 一本一本综合久久| av欧美777| 国产亚洲精品综合一区在线观看| 成人无遮挡网站| 久久国产乱子伦精品免费另类| 99热这里只有是精品50| 香蕉丝袜av| 成人av一区二区三区在线看| 久久伊人香网站| 18禁在线播放成人免费| 精品国产超薄肉色丝袜足j| 久久精品国产99精品国产亚洲性色| 久久精品影院6| 老熟妇乱子伦视频在线观看| bbb黄色大片| 18禁国产床啪视频网站| 成人永久免费在线观看视频| 一级作爱视频免费观看| 国产主播在线观看一区二区| 天堂av国产一区二区熟女人妻| 欧美在线一区亚洲| 好男人电影高清在线观看| 黄色丝袜av网址大全| 深爱激情五月婷婷| 不卡一级毛片| 色尼玛亚洲综合影院| 国产精品自产拍在线观看55亚洲| 午夜两性在线视频| 成熟少妇高潮喷水视频| 欧美日韩中文字幕国产精品一区二区三区| 黄色成人免费大全| 成年免费大片在线观看| 国产黄a三级三级三级人| 国产精品99久久99久久久不卡| 三级毛片av免费| 91麻豆精品激情在线观看国产| 亚洲无线观看免费| 成人av在线播放网站| 久久精品国产清高在天天线| www日本在线高清视频| 亚洲人成伊人成综合网2020| 亚洲国产欧洲综合997久久,| 波野结衣二区三区在线 | 亚洲 国产 在线| 国产在线精品亚洲第一网站|